Combination of hyaluronic acid hydrogel and bone marrow mesenchymal stem cells promotes cardiac function after myocardial infarction in rats (II)

doi:10.3969/j.issn.2095-4344.2106

Abstract

Abstract:

BACKGROUND: Our previous experimental results have shown that hyaluronic acid (HA) hydrogel can act as a vehicle for bone marrow mesenchymal stem cell (BMSC) delivery to improve the cardiac function of rats with myocardial infarction.

OBJECTIVE: To explore the effects of BMSCs encapsulated in HA hydrogel on histological changes of the rat myocardium after myocardial infarction.

METHODS: BMSCs from male Sprague-Dawley rats were isolated and cultured, and then HA-encapsulated BMSCs were cultured in vitro in the three-dimensional manner. A model of myocardial infarction was made by ligating the left anterior descending artery of female Sprague-Dawley rats. After 1 week, the model rats were screened by ultrasonic testing and then eligible ones were randomly divided into four groups: PBS group (n=8), HA group (n=8), BMSCs group (n=29), and HA-encapsulated BMSCs group (n=29). At 1 week after ligation, the model rats underwent the secondary thoracotomy followed by corresponding injections into the infarcted region and its marginal zone. At 4 week after injection, cardiovascular regeneration, myocardial protection, and ventricular remodeling were evaluated using hematoxylin-eosin staining, Masson’s staining and immunohistochemical staining, respectively.

RESULTS AND CONCLUSION: At 4 weeks after transplantation, compared with the PBS group, the infarcted ventricular wall was thickened in the HA group, cardiomyocyte hypertrophy was relieved and neovascularization was increased in the BMSCs group, and the largest benefits were indicated in the HA-encapsulated BMSCs group by reversing cardiac remodeling, increasing neovascularization and viable myocardium tissues in the infarct zone. Therefore, the HA-encapsulated BMSCs can achieve the best effect in the treatment of myocardial infarction.

Key words: hyaluronic acid">, , bone marrow mesenchymal stem cell">, , myocardial infarction">, , cell transplantation">, , cardiac function">, , stem cells

CLC Number:

Shang Qingqing, Zhou Jianye. Combination of hyaluronic acid hydrogel and bone marrow mesenchymal stem cells promotes cardiac function after myocardial infarction in rats (II)[J]. Chinese Journal of Tissue Engineering Research, 2020, 24(34): 5559-5563.

Figures/Tables 2

References

[1] RUSSO V, YOUNG S, HAMILTON A, et al. Mesenchymal stem cell delivery strategies to promote cardiac regeneration following ischemic injury. Biomaterials. 2014;35(13):3956-3974.

[2] SUTTON MG, SHARPE N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101(25): 2981-2988.

[3] LI Z, HU S, CHENG K. Chemical Engineering of Cell Therapy for Heart Diseases. Acc Chem Res. 2019;52(6):1687-1696.

[4] SHAFIQ M, LEE SH, JUNG Y, et al. Strategies for recruitment of stem cells to treat myocardial infarction. Curr Pharm Des. 2015;21(12): 1584-1597.

[5] RABBANI S, SOLEIMANI M, SAHEBJAM M, et al. Simultaneous Delivery of Wharton's Jelly Mesenchymal Stem Cells and Insulin-Like Growth Factor-1 in Acute Myocardial Infarction. Iran J Pharm Res. 2018; 17(2):426-441.

[6] KLYACHKIN YM, IDRIS A, RODELL CB, et al. Cathelicidin Related Antimicrobial Peptide (CRAMP) Enhances Bone Marrow Cell Retention and Attenuates Cardiac Dysfunction in a Mouse Model of Myocardial Infarction. Stem Cell Rev Rep. 2018;14(5):702-714.

[7] SANGANALMATH SK, BOLLI R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013;113(6):810-834.

[8] HASAN A, KHATTAB A, ISLAM MA, et al. Injectable Hydrogels for Cardiac Tissue Repair after Myocardial Infarction. Adv Sci (Weinh). 2015; 2(11):1500122.

[9] YAO Y, LIAO W, YU R, et al. Potentials of combining nanomaterials and stem cell therapy in myocardial repair. Nanomedicine (Lond). 2018; 13(13):1623-1638.

[10] UITTERDIJK A, GROENENDIJK BCW, GORSSE-BAKKER C, et al. Time course of VCAM-1 expression in reperfused myocardial infarction in swine and its relation to retention of intracoronary administered bone marrow-derived mononuclear cells. PLoS One. 2017;12(6):e0178779.

[11] 商青青,周建业,李凯,等.透明质酸水凝胶包裹骨髓间充质干细胞改善大鼠心肌梗死后心功能[J].中国组织工程研究, 2018,22(5):675-679.

[12] ZHOU Q, ZHOU JY, ZHENG Z, et al. A novel vascularized patch enhances cell survival and modifies ventricular remodeling in a rat myocardial infarction model. J Thorac Cardiovasc Surg. 2010;140(6): 1388-1396.

[13] FISHBEIN MC, MACLEAN D, MAROKO PR. Experimental myocardial infarction in the rat: qualitative and quantitative changes during pathologic evolution. Am J Pathol. 1978;90(1):57-70.

[14] DURAN JM, MAKAREWICH CA, SHARP TE, et al. Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms. Circ Res. 2013;113(5):539-552.

[15] KATARZYNA R. Adult Stem Cell Therapy for Cardiac Repair in Patients After Acute Myocardial Infarction Leading to Ischemic Heart Failure: An Overview of Evidence from the Recent Clinical Trials. Curr Cardiol Rev. 2017;13(3):223-231.

[16] WILLIAMS AR, HARE JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109(8):923-940.

[17] BAREEQA SB, BIBI F, AHMED SI, et al. Advancement in Stem Cell Therapy for Ischemic Myocardial Cell: A Systematic Review. Int J Hematol Oncol Stem Cell Res. 2018;12(4):282-290.

[18] HAMDI H, FURUTA A, BELLAMY V, et al. Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison. Ann Thorac Surg. 2009;87(4):1196-1203.

[19] MOUNT S, KANDA P, PARENT S, et al. Physiologic expansion of human heart-derived cells enhances therapeutic repair of injured myocardium. Stem Cell Res Ther. 2019;10(1):316.

[20] PASSIER R, VAN LAAKE LW, MUMMERY CL. Stem-cell-based therapy and lessons from the heart. Nature. 2008;453(7193):322-329.

[21] JOHNSON TD, CHRISTMAN KL. Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction. Expert Opin Drug Deliv. 2013;10(1):59-72.

[22] LE LV, MOHINDRA P, FANG Q, et al. Injectable hyaluronic acid based microrods provide local micromechanical and biochemical cues to attenuate cardiac fibrosis after myocardial infarction. Biomaterials. 2018; 169:11-21.

[23] TOUS E, IFKOVITS JL, KOOMALSINGH KJ, et al. Influence of injectable hyaluronic acid hydrogel degradation behavior on infarction-induced ventricular remodeling. Biomacromolecules. 2011;12(11):4127-4135.

[24] WANG N, LIU C, WANG X, et al. Hyaluronic Acid Oligosaccharides Improve Myocardial Function Reconstruction and Angiogenesis against Myocardial Infarction by Regulation of Macrophages. Theranostics. 2019; 9(7):1980-1992.